OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Resolving operational bottlenecks makes mAb manufacturing more efficient.
Experts discuss what data to consider when selecting a high-potential drug candidate.
Bacteriophages could be crucial weapons in the fight against antibiotic-resistant bacteria.
July 03, 2022
Single-cell analytical technologies can deepen the understanding of cell biology and, therefore, disease mechanisms.
June 30, 2022
Inceptor Bio and the University of Minnesota aim to build a novel iPSC platform to accelerate cell therapy drug development.
June 27, 2022
ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.
The Sanofi-GSK vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial with a high-Omicron environment.
June 24, 2022
Novartis will endorse the Kigali Declaration on neglected tropical diseases and invest $250 million for R&D.
GSK will invest £1 billion in furthering R&D in malaria, tuberculosis, and HIV, as well as neglected tropical diseases.
June 21, 2022
Avid Bioservices has expanded its viral vector development and manufacturing facility with the addition of analytical and process development suites.
Orbit Discovery has been awarded the Innovate UK Grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery.
June 17, 2022
A new polymer surface material has been invented by researchers in Sweden that uses electrical signals to both capture and release biomolecules.
June 13, 2022
Precision BioSciences has released clinical trial data on CAR T therapy candidates PBCAR0191, PBCAR19B, and PBCAR269A.